Cipla’s India sales rise 12% as it leans on consumer-health expansion
Cipla posted record India sales of ₹3,452 crore in the June quarter, with the market contributing 48% of revenue. The drugmaker is using its ₹10,094 crore cash position to explore biologics and underrepresented Indian healthcare segments while monitoring US tariff exposure.
Cipla reported record India sales of ₹3,452 crore, up 12%, while Q1 PAT fell 39%. It is selling a second Eli Lilly Mounjaro brand and may pursue biologics and other underrepresented India segments using ₹10,094 crore cash.
Why this matters
The result follows Cipla’s recent Q1FY27 signal, where profit fell 39% despite record India sales, underscoring India growth as the company weighs consumer health, biologics and other underserved care segments.
Retail-company signals are accelerating, up 1,055,100% QoQ.